More than a third of babies suspected of having a peanut allergy can safely have the diagnosis removed after undergoing a supervised oral food challenge, according to a world-first national program.
Researchers evaluated 1,275 infants under 18 months old, with 778 undergoing an oral food challenge at 10 pediatric public hospitals across Australia. The evaluation forms part of the ADAPT Peanut Oral Immunotherapy Program, launched in 2024 by the National Allergy Centre of Excellence and hosted at the Murdoch Children’s Research Institute.
The evaluation revealed that 34.8% of challenged infants had a negative result and safely had their peanut allergy label removed. Without this supervised challenge, these children would have likely continued avoiding peanuts indefinitely.

Among the infants who did react during the testing process, 65% experienced symptoms, including 12% who suffered anaphylaxis. All of these reactions were safely managed by the medical teams conducting the procedures.
For the infants who reacted, 97.5% successfully started oral immunotherapy at a dose guided by their individual challenge threshold. Dr. Tim Brettig, a senior research clinician in the Murdoch Children’s Research Institute Population Allergy Group and ADAPT medical lead, emphasized the impact of these findings.
“We found more than one third of infants who were suspected to have peanut allergy based on their history and initial tests no longer reacted when they underwent a supervised food challenge,” Brettig said. “Being able to identify those children early allows them to avoid an unnecessary allergy label and the burden of avoiding peanut.”
Australia maintains some of the highest childhood food allergy rates globally, with peanut allergies affecting approximately one in 30 children. Professor Kirsten Perrett, director of the National Allergy Centre of Excellence and leader of the Murdoch Children’s Research Institute Population Allergy Group, said that current clinical practices must adapt to these findings.
“Oral food challenges are not currently used routinely for every infant with suspected peanut allergy,” Perrett said. “But our results show that clinical history and allergy testing alone were not enough to accurately diagnose peanut allergy in many cases. A supervised oral food challenge should be routinely considered to confirm the diagnosis before an infant starts oral immunotherapy.”
Skin and blood tests frequently produce false positives despite rarely yielding false negatives. Consequently, infants presenting with a convincing history but low test values may benefit from a supervised challenge to determine true tolerance.
The ADAPT program plans to reassess infants with negative food challenges at two years of age to verify whether any individuals subsequently redevelop a peanut allergy.
Related reading